KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to -$454.5 million.

  • Ionis Pharmaceuticals' Consolidated Net Income rose 8.45% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$257.0 million, marking a year-over-year increase of 28.53%. This contributed to the annual value of -$454.5 million for FY2024, which is 23.84% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$454.5 million for FY2024, which was down 23.84% from -$367.0 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Consolidated Net Income high stood at -$29.4 million for FY2021, and its period low was -$482.4 million during FY2020.
  • Over the past 3 years, Ionis Pharmaceuticals' median Consolidated Net Income value was -$367.0 million (recorded in 2023), while the average stood at -$363.9 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Consolidated Net Income surged by 93.90% in 2021, and later tumbled by 818.68% in 2022.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Consolidated Net Income stood at -$482.4 million in 2020, then soared by 93.90% to -$29.4 million in 2021, then tumbled by 818.68% to -$270.2 million in 2022, then crashed by 35.82% to -$367.0 million in 2023, then declined by 23.84% to -$454.5 million in 2024.